Mirum CFO’s Latest 10b5‑1 Sale Signals Ongoing Insider Outflows Amid Stock’s Low‑End Decline.

Insider Selling Continues to Shake Up Mirum’s Share Price

In the latest Form 4 filing, Chief Financial Officer Eric Bjerkholt sold 6,001 shares of Mirum Pharmaceuticals common stock at an average price of $99.90, just shy of the current market price of $98.97. This transaction, executed under a Rule 10b5‑1 plan, is part of a broader pattern of frequent selling by senior officers that has been on the radar of investors for months. The sale comes after a week of heavy trading by other executives, including CEO Christopher Peetz, who has also been liquidating substantial positions. While the sale volume is modest relative to the company’s market cap ($6.54 billion), it signals a continued willingness among insiders to realize gains as the stock’s valuation hovers near its 52‑week low of $63.23.

What This Means for Investors

For shareholders, the cumulative insider activity suggests a potential short‑term bearish sentiment. The recent selling spree—spanning from March through August—has reduced the insiders’ overall holdings from a high of 57,075 shares in March to just 36,355 after Bjerkholt’s latest sale. This erosion of ownership stakes may raise concerns about management’s confidence in the company’s near‑term prospects, especially given the stock’s steep decline of 16.86 % over the past month. However, insiders continue to maintain substantial positions (over 36 000 shares), indicating that they still see long‑term value in Mirum’s therapeutic pipeline. Analysts should watch whether the trend of selling persists or stabilizes, as continued outflows could depress the stock further, while a slowdown might support a rebound.

Bjerkholt’s Trading Profile

Bjerkholt’s insider trading history paints a picture of a cautious but active executive. Since March 2026, he has made 18 transactions, with 12 sales and 6 purchases. His most aggressive sell was 7,287 shares at $91.98 in mid‑March, followed by a series of smaller sales at higher prices in July and August. He has also bought shares, notably 13,334 shares in March at an undisclosed price, and 2,393 shares in early June for $26.49—an unusually low price that suggests a strategic acquisition of undervalued shares. The mix of sales and purchases suggests that Bjerkholt is managing his holdings to balance liquidity needs while maintaining a long‑term stake in the company. His use of a Rule 10b5‑1 plan for the August sale underscores a preference for pre‑arranged, rule‑compliant selling rather than opportunistic trades.

Market Context and Outlook

Mirum’s stock has shown a mixed trajectory: a 52‑week high of $130, a year‑high of $98.23, and a steep yearly decline of 52.66 %. The company’s price‑earnings ratio of –6.14 indicates that investors are pricing in negative earnings expectations, likely due to the still‑nascent pipeline of cholestatic liver disease therapies. Despite the negative sentiment (social media buzz at 0.00 % and neutral sentiment scores), the company remains a high‑risk, high‑potential play for investors willing to wait for clinical milestones. Insider selling, while a cautionary sign, does not necessarily foretell a downward trajectory—especially if the sales are part of a broader liquidity strategy and insiders retain sizeable positions. Investors should monitor upcoming regulatory filings, clinical trial updates, and any shifts in insider ownership to gauge whether the stock is primed for a rebound or further consolidation.